Faulty reasoning signals

• Confirmation Bias - 5.4% (15 hits)
• Anchoring Bias - 0%
• Availability Heuristic - 8.6% (24 hits)
• Representativeness Heuristic - 5.8% (16 hits)
• Hindsight Bias - 0%
• Overconfidence Bias - 0%
• Framing Effect - 13.3% (37 hits)
• Loss Aversion - 6.5% (18 hits)
• Status Quo Bias - 0%
• Sunk Cost Effect - 0%
• Optimism Bias - 16.9% (47 hits)
• Pessimism Bias - 0%

Article text

The biotech scorecard for the third quarter: 15 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Amylyx Pharmaceuticals: Results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia, a rare metabolic condition that causes severe drops in blood sugar.

Biogen: In May, the company announced results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease called diranersen that targets the protein tau.

Detailed data from the study will be presented on July 14 at the Alzheimer’s Association International Conference.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

STAT+ Newsletter

Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world

Recommended

STAT Plus: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong

STAT Plus: A year after distressed buyout, what’s become of Bluebird Bio?

Advertisement

STAT Plus: Synthetic biology researchers think they’ve made a cell.

Is it alive?

STAT Plus: More signs that GLP-1s may help with peripheral artery disease

STAT Plus: FDA approves Orca Bio’s T cell therapy for blood cancer patients

Subscriber Picks

STAT Plus: The ERs that can turn patients away — and are reaping millions

STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry

STAT Plus: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient.

Who was it?

STAT Plus: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk

STAT Plus: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes